Patents Assigned to MedImmune Limited
  • Engineered O-glycosylation in recombinant polypeptides and uses thereof
    Patent number: 11834473
    Abstract: The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides may be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labelling.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 5, 2023
    Assignee: MedImmune Limited
    Inventors: Adam Tibbles, Monika Papworth, Daniel Higazi, Emmanuel Rossy, Katarzyna Anna Kozakowska, Thomas Vincent Murray
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11813335
    Abstract: A conjugate of formula (I): Ab-(DL)p??(I) wherein: Ab is an antibody that binds to AXL; DL is
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: November 14, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Heterodimeric Relaxin fusions polypeptides
    Patent number: 11795205
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: October 24, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
  • Therapeutic binding molecules
    Patent number: 11795225
    Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 24, 2023
    Assignee: MedImmune Limited
    Inventors: Krista Lynne Kinneer, Gareth Charles Davies, David Gareth Rees, Jennifer Louise Percival-Alwyn, John Edward Andrews, Jon Chesebrough
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11779650
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 10, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Antibodies to ticagrelor and methods of use
    Patent number: 11773186
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: October 3, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11771775
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 3, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20230303707
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Application
    Filed: February 14, 2023
    Publication date: September 28, 2023
    Applicant: MEDIMMUNE LIMITED
    Inventors: Rachel Patricia MOATE, Alex GODWOOD, Ethan Paul GRANT, Martin Michael Kari SCHWICKART, Carlos CHAVEZ, Meina LIANG, Tomas Mikael MUSTELIN, Zhengbin YAO, Koustubh RANADE
  • Polynucleotides encoding IL33 antibodies and methods of using the same
    Patent number: 11738081
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 29, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • Pyrrolobenzodiazepines and conjugates thereof
    Patent number: 11701430
    Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: July 18, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Site-specific antibody-drug conjugates
    Patent number: 11702473
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: July 18, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Peptidomimetic compounds and antibody-drug conjugates thereof
    Patent number: 11692043
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: July 4, 2023
    Assignees: MEDIMMUNE LIMITED, GENENTECH, INC.
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
  • Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
    Patent number: 11690918
    Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: July 4, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Anti-RSV monoclonal antibody formulation
    Patent number: 11667698
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: June 6, 2023
    Assignee: MedImmune Limited
    Inventors: Brian Lobo, Deborah Goldberg
  • RSV-specific antibodies and functional parts thereof
    Patent number: 11661449
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: May 30, 2023
    Assignee: MedImmune Limited
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Pyrrolobenzodiazepine conjugates
    Patent number: 11649250
    Abstract: A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: May 16, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Nazzareno Dimasi, Philip Wilson Howard, Luke Masterson, Arnaud Charles Tiberghien, Balakumar Vijayakrishnan, Jason White
  • Nucleic acids encoding anti-VEGF-A antibodies and uses thereof
    Patent number: 11634483
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: April 25, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11612665
    Abstract: A conjugate of formula (I): Ab-(DL)p wherein: Ab is an antibody, or an active fragment of an antibody; DL is (II).
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 28, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
    Patent number: 11613580
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: March 28, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Rachel Patricia Moate, Alex Godwood, Ethan Paul Grant, Martin Michael Kari Schwickart, Carlos Chavez, Meina Liang, Tomas Mikael Mustelin, Zhengbin Yao, Koustubh Ranade
  • Combination therapy with an anti-CD25 antibody-drug conjugate
    Patent number: 11596696
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: March 7, 2023
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley